Snibe

Snibe Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a bio-medical company specialize Snibe's striving for excellence never ends.

(Snibe) is located in National Biological Industry Park, Shenzhen, China. Since 1995, Snibe has focused on IVD field for 30 years and also become the first chemiluminescence immunoassay manufacturer who got FDA cleared in China. With four core R&D centers, including reagent, instrument, magnetic microbead, and reagent raw material, Snibe develops a wide range of CLIA test menus. Now, Snibe's products have spread to 161 countries globally with installations of about 40,000 units. To be the pioneer in the global diagnosis field is our vision.

02/04/2026

🎬 Lumi Talk | Episode 4: Working at Snibe🌍

New episode out now! 🎙 We invited our international training specialist Fady Farouk to share what it's really like to work at Snibe.

From first impressions to daily moments that make him feel at home—this one's full of honest stories and good vibes.

How about your work life? Share in the comments!

Tune in now 👉🔗https://youtu.be/1CZc9MElkT8

April is STI Awareness Month, observed to raise public awareness of sexually transmitted infections (STIs).Worldwide, ap...
01/04/2026

April is STI Awareness Month, observed to raise public awareness of sexually transmitted infections (STIs).

Worldwide, approximately one million new curable STIs are reported each day. Getting tested for STIs and staying sexually healthy is increasingly important. This month, we invite you to explore Snibe's reliable and comprehensive testing solutions that help you take charge of your health with confidence: https://www.snibe.com/en/product/CLIA_menu/

Let's make self-care a priority. You deserve to feel safe and empowered!

As chronic liver diseases (CLD) are common global health issue, novel circulating markers for the non-invasive staging o...
31/03/2026

As chronic liver diseases (CLD) are common global health issue, novel circulating markers for the non-invasive staging of the diseases are in high demand. Snibe MAGLUMI provides a broad parameters of HA, LN, PIIIP N-P, C-IV, CG and GP73, which are related to hepatic fibrosis. We are also happy to share a high-quality research conducted by teams from Italy. This study underscores the potential of these extracellular matrix in non-invasive staging CLD. Combined with AI, machine learning could further enhance diagnositc accuracy and reduce the need for invasive biopsies.

Please find the link to the original paper:
https://www.sciencedirect.com/science/article/pii/S0009912024001553

Fibrosis learning

26/03/2026

🎬 Lumi Talk | Episode 3: Snibe-NACA Technology Redefines Accuracy

High sensitivity, high accuracy, high throughput and cost-efficiency How to have all? This is a question.
Say "Hi" with Lumi! He will address your question with Ray, the Head of Scientific Affairs of Int'l Marketing of Snibe.

Let's watch the full video to find out the answer👉🔗https://youtu.be/h7EYRIkRvI0

25/03/2026

🎬 Lumi Talk | Episode 2: What does "SNIBE" mean?

Lumi is back! Snibe had been well-known around the world, but do you know what the meaning of Snibe is?🤔
In this video, Lumi stands with Vincent, the Head of Global Marketing of Snibe, to discover the real meaning for us.

Can't wait to watch the full video👉🔗https://youtu.be/r1AVfTUXJ_k

March 24 marks a global call to action against one of the world's deadliest infectious diseases -- tuberculosis (TB). It...
24/03/2026

March 24 marks a global call to action against one of the world's deadliest infectious diseases -- tuberculosis (TB). It's an airborne infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs, but it can also affect other parts of your body.

Annually, an estimated 10.6 million people fall ill with TB, with 1.3 million deaths around the world. But it's preventable and curable.

This , Snibe empowers reliable diagnostic solutions to help early detection and better outcomes for all to fight the disease.

Yes! Let's end the TB together!

It's not just "growing pains".Young rheumatic diseases, also known as pediatric rheumatic illnesses, are conditions in c...
18/03/2026

It's not just "growing pains".
Young rheumatic diseases, also known as pediatric rheumatic illnesses, are conditions in children under 16 that cause the immune system to be overactive, leading to inflammation. They most often affect the musculoskeletal system — including joints, bones, and muscles — but can also involve other parts of the body, like the skin, eyes, and organs. They affect 1 to 4 in every 1,000 children worldwide.

Because symptoms are sometimes dismissed or mistaken for growing pains, early detection is usually key to getting a correct diagnosis and early treatment. At Snibe, we help close that gap. Our comprehensive autoimmune diagnostic solutions support early and accurate detection: https://www.snibe.com/en/product/CLIA_menu/

On this World Young Rheumatic Diseases Day, let's protect young futures via early diagnosis!

16/03/2026

Welcome to Lumi Talk —a brand new series where our curious mascot, Lumi, steps out from behind the brand and into conversations with KOLs!

In the premiere episode, Lumi stands with Prof. Tomas Zima, the president of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), to discuss his impression of SNIBE.

Watch the full interview here: https://youtu.be/hLQwMs6sksU

What if you could double your throughput without doubling your lab space? 🤔Meet MAGLUMI® X10 — Fully-auto Chemiluminesce...
13/03/2026

What if you could double your throughput without doubling your lab space? 🤔

Meet MAGLUMI® X10 — Fully-auto Chemiluminescence Immunoassay (CLIA) System, the high space utilization that fits large test needs at one time.

The X10 solution:
✅ 1000 tests/hour in just ~2.4 m²
✅ 50 reagents + 300 samples onboard
✅ 3000 walk-away tests — load once, run longer

Same footprint, More output, Less labor. 👉 See how X10 fits your lab: https://www.snibe.com/en/product/CLIA_analyzer/342.html

On World Kidney Day, we highlight the "silent disease". Chronic Kidney Disease (CKD) affects 850 million people globally...
12/03/2026

On World Kidney Day, we highlight the "silent disease". Chronic Kidney Disease (CKD) affects 850 million people globally, with a death occurring every 20 seconds. If trends continue, CKD is set to become the 5th leading cause of death by 2050.

Early-stage CKD is asymptomatic but easily detectable. Early detection help protect kidney health and save lives. At Snibe, our comprehensive and accurate solutions support the clinical guidelines for screening at-risk populations: https://www.snibe.com/en/product/biochemistry_menu/

Join us in the fight against kidney disease!

Anemia is a prevalent condition characterized by a lack of healthy red blood cells in the blood, leading to symptoms suc...
11/03/2026

Anemia is a prevalent condition characterized by a lack of healthy red blood cells in the blood, leading to symptoms such as fatigue, weakness, and pale skin. Diagnosis typically involves blood tests, and treatment approaches vary depending on the underlying cause. For more information, you can refer to this article: https://www.snibe.com/en/news/list/668.html

We are extremely honored to share a new paper from Clinica Chimica Acta on the Snibe-NACA technology (Snibe small molecu...
10/03/2026

We are extremely honored to share a new paper from Clinica Chimica Acta on the Snibe-NACA technology (Snibe small molecule sandwich reagent estradiol assay). Estradiol is a key estrogen, and measuring its circulating levels is essential for evaluating ovarian function, and assessing reproductive health.
Due to the restricted molecular volume and steric hindrance, small molecular compounds usually possess only one epitope, leading to the adoption of a competitive method in traditional immunoassays. However, these constraints contribute to inherent analytical limitations, particularly in achieving requisite sensitivity and specificity. To address these methodological challenges, Snibe developed the Snibe-NACA technology to enhance higher sensitivity and precision. This study demonstrates that the Snibe MAGLUMI Estradiol sandwich assay exhibits higher sensitivity and precision, representing significant advancement over consistency with the results of LC-MS/MS.

Please find the link to the original paper below.
https://www.sciencedirect.com/science/article/abs/pii/S0009898125002359?via%3Dihub

Address

Shenzhen

Opening Hours

Monday 08:30 - 18:00
Tuesday 08:30 - 18:00
Wednesday 08:30 - 18:00
Thursday 08:30 - 18:00
Friday 08:30 - 18:00

Telephone

+8675528292700

Alerts

Be the first to know and let us send you an email when Snibe posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Snibe:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram